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Summary
The Janus kinase (Jak) family is one of ten recognized families of non-receptor tyrosine kinases.
Mammals have four members of this family, Jak1, Jak2, Jak3 and Tyrosine kinase 2 (Tyk2). Birds,
fish and insects also have Jaks. Each protein has a kinase domain and a catalytically inactive
pseudo-kinase domain, and they each bind cytokine receptors through amino-terminal FERM
(Band-4.1, ezrin, radixin, moesin) domains. Upon binding of cytokines to their receptors, Jaks are
activated and phosphorylate the receptors, creating docking sites for signaling molecules,
especially members of the signal transducer and activator of transcription (Stat) family. Mutations
of the Drosophila Jak (Hopscotch) have revealed developmental defects, and constitutive
activation of Jaks in flies and humans is associated with leukemia-like syndromes. Through the
generation of Jak-deficient cell lines and gene-targeted mice, the essential, nonredundant
functions of Jaks in cytokine signaling have been established. Importantly, deficiency of Jak3 is the
basis of human autosomal recessive severe combined immunodeficiency (SCID); accordingly, a
selective Jak3 inhibitor has been developed, forming a new class of immunosuppressive drugs.
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Gene organization and evolutionary history 
Janus kinases (Jaks) are non-receptor tyrosine kinases and
were discovered in searches for novel protein tyrosine
kinases using PCR-based strategies or low-stringency
hybridization [1-6]. In mammals, the family has four
members, Jak1, Jak2, Jak3 and Tyrosine kinase 2 (Tyk2). In
humans, the Jak1 gene is located on chromosome 1p31.3 and
Jak2 is on 9p24; the Jak3 and Tyk2 genes are clustered
together on chromosome 19p13.1 and 19p13.2, respectively.
The murine genes are located on chromosomes 4 (Jak1), 19
(Jak2) and 8 (Jak3 and Tyk2). Since the sequencing of other
vertebrate genomes has been completed, we know that there
are four Jak family members in mammals, birds and fish
(see the Additional data files available with the online
version of this article for alignments). 
Jaks have been identified in the primitive chordate Ciona; it
is unclear, however, whether this species only has a single
Jak or whether more will be found with further sequencing
(see Additional data files). In Drosophila there is only one
Jak kinase, Hopscotch (Hop) [7,8]. The ancestral Jak must
therefore have arisen before the divergence of vertebrates
and invertebrates. Nematode worms and slime molds lack
the family, however, but they do express members of the
signal transducer and activator of transcription (Stat) family
of transcription factors - which in vertebrates interact with
Jaks, among other proteins - suggesting that the Stats arose
in evolution before the Jaks. It is of interest that the expan-
sion of the Jak kinases in higher animals occurred at the
same time as the evolution of innate and adaptive immune
cells in fish; this is consistent with the multiple roles of Jaks
in immune cells (see below). Thus, cytokine receptors acting
via Jaks appear to have co-opted the Stat pathway for a variety
of purposes, especially for host defense. The proximity of the
Jak3 and Tyk2 genes suggests that one may have arisen from
the other by gene duplication, but it is difficult to conclude
which is the more ancestral. Jaks have approximately 20
exons; alternatively spliced forms of Jaks have been described
but their functional significance is not known. 
Characteristic structural features 
The three-dimensional structure of the Jaks is at present
unknown. This is no doubt partly because they are relatively
large proteins of more than 1,100 amino acids, with apparent
molecular masses of 120-140 kDa; expressing and purifying
them has been problematic. From the primary structure,
putative domain structures have been recognized that are
conserved between mammalian, avian, teleost and insect
Jaks. Seven Jak homology (JH) domains have been identi-
fied, numbered from the carboxyl to the amino terminus
(Figure 1). The JH1 domain at the carboxyl terminus has all
the features of a typical eukaryotic tyrosine kinase domain.
Interestingly, this domain is most closely related to the kinase
domains of the epidermal growth factor family of receptor
tyrosine kinases, suggesting that the Jak family may have
arisen from this larger family of protein kinases [9]. Adjacent
to the JH1 domain is a catalytically inactive pseudokinase or
kinase-like domain (JH2), which is distantly related to other
tyrosine kinase domains [9]. This tandem architecture of
kinase domains is the hallmark of Jak kinases and gives them
their name; just like the Roman god Janus, they are two-faced
with respect to these domains. Although the pseudokinase
domain lacks catalytic activity, it has an essential regulatory
function. A number of patient-derived and artificial muta-
tions within this domain abrogate kinase activity, underscor-
ing its critical function [10,11]. Conversely, a mutation within
this domain in Drosophila Hop activates the kinase and leads
to transformation (discussed below) [12-14]. In mammalian
Jak2, experimentally introduced mutations in this domain
can also increase basal activity, but they abrogate ligand-
dependent activation [11,15].
The amino terminus of Jaks contains an SH2-like domain
(JH3-JH4) and a Band-4.1, ezrin, radixin, moesin (FERM)
homology domain (JH6-JH7). The FERM domain is 300
amino acids long and is implicated in mediating interactions
with transmembrane proteins such as cytokine receptors; for
some but not all cytokines, Jaks appear to be important in
regulating cell-surface expression of the cognate receptors
[16,17]. In addition, the FERM domain binds the kinase
domain and positively regulates catalytic activity [18].
Unfortunately, the lack of crystal structures severely limits
the understanding of the intramolecular interactions that
involve Jaks. Binding partners for the Jak SH2 domain have
not been identified.
Localization and function  
In mammals Jak1, Jak2 and Tyk2 are ubiquitously
expressed. In contrast, the expression of Jak3 is more
restricted; it is predominantly expressed in hematopoietic
cells and is highly regulated with cell development and acti-
vation [6,19,20]. At the cellular level, Jaks can be found in
the cytosol when they are experimentally expressed in the
absence of cytokine receptors, but, because of their intimate
association with cytokine receptors, they ordinarily localize
to endosomes and the plasma membrane, along with their
cognate receptors [21,22]. The link between Jaks and
cytokine signaling was first made using mutant cell lines that
lacked responsiveness to interferon (IFN). One such cell line
was shown to lack Tyk2, and adding back this kinase
restored IFN signaling [16]. Shortly thereafter other Jaks
were shown to be associated with various cytokine receptors
[23-26], and subsequently Jak knockout mice have illus-
trated their essential and specific functions (see Table 1). 
A large number of cytokines are dependent upon Jak1,
including a family that use a shared receptor subunit called
common  chain (c), which includes interleukin (IL)-2,
IL-4, IL-7, IL-9, IL-15 and IL-21. These cytokines are also
dependent upon Jak3, because Jak3 binds c. Jak1 is also
essential for another family that uses the shared receptor
subunit gp130 (IL-6, IL-11, oncostatin M, leukemia
inhibitory factor (LIF), ciliary neurotrophic factor (CNF)) as
well as granulocyte colony-stimulating factor (G-CSF) and
IFNs. Jak2 is essential for the hormone-like cytokines such
as growth hormone (GH), prolactin (PRL), erythropoietin
(EPO), thrombopoietin (TPO) and the family of cytokines
that signal through the IL-3 receptor (IL-3, IL-5 and
granulocyte-macrophage colony-stimulating factor, GM-CSF).
Jak2 is also important for cytokines that use the gp130
receptor and for some IFNs. 
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Figure 1
A schematic representation of the primary structure of Janus kinases
(Jaks), which are made up of FERM, SH2-like, pseudokinase and kinase
domains. An alternative nomenclature for the putative domains is as a
series of Janus homology (JH) domains. The FERM domain mediates
binding to cytokine receptors. Both the FERM and the pseudokinase
domains regulate catalytic activity and appear to interact with the kinase
domain. Jaks autophosphorylate at multiple sites (P), including two in the
activation loop of the kinase domain, but the precise function of these
modifications is just beginning to be understood. 
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Tyk2 was the first Jak to be implicated in IFN signaling, but
subsequent studies indicate that Tyk2 is essential for IL-12
signaling but not for IFN- signaling or for cytokines that
use gp130 [27,28]. Tyk2-/- mice also have defective
responses to lipopolysaccharide (LPS, a component of the
outer membrane of Gram-negative bacteria), but whether
this is a direct or indirect effect has not been defined. In par-
ticular, a role for Tyk2 in signaling through the Toll receptor,
which mediates the response to LPS, has not been estab-
lished [29,30]. 
Jak1 knockout mice have a perinatal lethal phenotype, prob-
ably related to the neurological defects that prevent them
from suckling [30] (Table 1). These mice also have defective
lymphoid development and function as a result of defective
signaling by cytokines through Jak1. Jak2 deficiency results
in embryonic lethality at embryonic day 12.5 as a result of a
failure in definitive erythropoiesis [31,32]. Interestingly,
Jak3 deficiency was first identified in humans with autoso-
mal recessive severe combined immunodeficiency (SCID)
[33,34]. We now know that Jak3 binds to c and that defi-
ciency of either Jak3 or c abrogates signaling by the family
of cytokines using this receptor subunit. Not surprisingly,
this has devastating consequences in terms of immune-cell
development and function. Together, mutations in the
receptor for IL-7, c and Jak3 account for two-thirds to
three-quarters of cases of SCID [35]. Jak3-/- mice were sub-
sequently generated, and they too exhibit SCID but notably
do not have non-immune defects [36-38]; this is notable
because it suggests that an inhibitor of Jak3 would have
restricted effects in vivo ([35]; see below). 
The Jak/Stat pathway has been extensively studied in
Drosophila and has been demonstrated to be involved in
stem-cell maintenance, ovarian-cell migration and sex deter-
mination [13,39]. In development, this pathway is important
for embryonic segmentation and larval hematopoiesis as
well as for development of the eye, wing, trachea, hindgut
and limb [14,40-44]. A gain-of-function mutation in Hop
has been identified that results in a leukemia-like phenotype
in the affected flies; this is designated tumorous lethal
(Hoptum-l) [12,45,46]. In human leukemias, chromosomal
translocations result in fusion proteins of the Tel transcrip-
tion factor with Jaks. This creates a constitutively active Jak,
which has also been documented to be transforming [47,48].
In human cells transformed with T-cell leukemia virus-1,
Jak3 and Stat5 are constitutively activated [49]. Constitutive
activation of Stats is very common in many other types of
tumors, although the mechanisms underlying this activation
have yet to be defined. 
Jaks are constitutively associated with the membrane-proxi-
mal regions of cytokine receptors, although in some cases
interaction between the Jak and the receptor is increased
upon ligand binding (Figure 2). It has been proposed that
ligand binding promotes a conformational change in the
receptor, which promotes Jak activation through reciprocal
interaction of two juxtapositioned Jak kinases and auto-
and/or trans-phosphorylation of tyrosine residues on the
activation loop of the Jak kinase domain.
Like other tyrosine kinases, Jaks undergo autophosphoryla-
tion, but the importance of this modification in Jak-dependent
signaling is not very well understood. Autophosphorylation
within the activation loop positively regulates kinase activity; in
Jak3, however, phosphorylation in this region can enhance or
inhibit catalytic activity, depending upon the site of phosphory-
lation [50] (Figure 1). Other sites of autophosphorylation have
recently been identified. For instance, a conserved residue in
Jak2 and Jak3 that resides in the hinge region between JH1
and JH2 is a prominent site of autophosphorylation (Tyr813 in
Jak2 and Tyr785 in Jak3) [51]. This site serves to recruit the
adapter protein SH2-B, which positively regulates Jak2 activ-
ity. Other sites of autophosphorylation in Jak2 include Tyr221
and Tyr570 [52]. 
Frontiers 
Despite intensive studies during the past decade that have
generated the model shown in Figure 2, the exact molecular
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Table 1
Functions of Jaks 
Gene Phenotype of mouse knockout Cytokines whose signaling requires this Jak
Jak1 Viable but early postnatal lethal owing to neurological deficits; SCID Families of receptor with the shared subunits c or gp130; IFNs
Jak2 Embryonic lethal owing to a defect of erythropoiesis IL-3; family of receptors with the shared subunit gp130; IFN-; 
hormone-like cytokines (EPO, GH, PRL, TPO)
Jak3 SCID, viable and fertile Family of receptor with the shared subunit c
Tyk2 Viable and fertile; susceptible to parasite infection; resistant to LPS; IL-12; LPS
resistant to collagen-induced arthritis
Abbreviations: EPO, erythropoietin; c, common  chain; GH, growth hormone; IFN, interferon; IL, interleukin; LPS, bacterial lipopolysaccharide; 
PRL, prolactin; SCID, severe combined immunodeficiency; TPO, thrombopoietin.
mechanisms of Jak activation have largely remained elusive.
It is clear that much more detailed structural information
pertaining to Jaks and the Jak-cytokine-receptor complex is
needed to enhance our understanding of the mechanism of
Jak activation. Also, the exact mechanism and functional rel-
evance of autophosphorylation at different sites in Jaks is
not known but will be an interesting area for future research. 
Another important topic for future studies is to define the
mechanisms of crosstalk between Jaks and other pathways.
For instance, the receptor Notch has been reported to
promote Stat3 activation, and the Notch effectors Hes1 and
Hes5 have been found to associate directly with Jak2 and
Stat3 [53]. Evidence for cooperation between the Jak/Stat
and Notch pathways has also been provided by work from
Drosophila [54] and genetic screens in Drosophila have
identified additional potential modifiers of the Jak/Stat
pathway [55]. Jaks have also been reported to be activated
by a variety of structurally diverse receptors, beyond the
cytokine receptors. Examples include receptor tyrosine
kinases, death receptors (such as CD40) and G-protein-
coupled receptors (such as chemokine receptors). Many of
the studies have employed overexpression or putatively spe-
cific inhibitors to implicate the Jaks, but we now know that
these inhibitors are not specific, so the essential function of
Jaks for non-cytokine receptors remains uncertain. This is
clearly another critical area for future work. 
Finally, because of the crucial role of Jak3 in cytokine signal-
ing through c and because of its limited tissue expression,
the inhibition of Jak3 activity has emerged as a promising
strategy for immunosuppression. A highly selective and
potent Jak3 inhibitor (CP-690,550) has recently been devel-
oped that has nanomolar potency against Jak3 in vitro, with
much less potency against other Jak family members. Conse-
quently, CP-690,550 was both very efficacious and well-toler-
ated in animal models of organ transplantation [56]. One
might anticipate that this drug will help to overcome the
unwarranted side effects often seen in patients under current
immunosuppressive therapy. Thus, the drug could be useful
in blocking transplant rejection and in the treatment of
autoimmune diseases. Conceivably, it might also be useful in
treating those hematological malignancies that exhibit consti-
tutive Jak3 activation. Targeting Tyk2 with specific drugs
would also be logical, given its restricted role; presumably a
Tyk2 inhibitor would be useful in some immune-mediated
diseases. Whether a Jak2 inhibitor would be useful in malig-
nancies is also worthy of consideration. 
Additional data files 
Protein sequence alignments in text and jpeg format are
available with the online version of this article for orthologs
of Jak1 (Additional data files 1 and 6), Jak2 (Additional data
files 2 and 7), Jak3 (Additional data files 3 and8), Tyk2
(Additional data files 4 and 9), and undefined members of
the family (Additional data files 5 and 10), and a key for the
alignments (Additional data file 11). 
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